Gilgamesh Pharma
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | NMDA receptorSmall molecule | Major Depressive Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
6 January 2026Topline resultblixeprodil (GM-1020)Phase 2a study of blixeprodil (GM-1020) in MDD: positive topline results
Gilgamesh Pharma · Source ↗
Financial reports
No financial reports recorded.